FDA Warning Letter Lessons: Sterility Assurance, Investigations & Visible Particulate Control

1. Why This FDA Warning Letter Matters

On September 22, 2026, the U.S. Food and Drug Administration issued a Warning Letter to Fresenius Kabi USA LLC following an inspection of its Melrose Park, Illinois drug manufacturing facility conducted from January 27 through February 18, 2026.

The facility manufactures sterile injectable drug products primarily through aseptic processing. FDA identified significant CGMP deficiencies involving investigations, aseptic process simulations, cleanroom practices, visible particulate inspection, contamination control, facility and equipment design, and quality-system oversight.

The regulatory lesson extends beyond this individual facility: sterility assurance cannot depend solely on acceptable finished-product test results. It must be built into the manufacturing process and supported by scientifically sound investigations, process controls, facility design, monitoring, and effective CAPA.

2. Passing Sterility Testing Does Not Close an Investigation

One of the most important themes in the Warning Letter concerns investigation quality.

FDA stated that investigations lacked data-supported root causes, appropriate documentation, adequate expansion to potentially affected products, and CAPA effectiveness checks. The agency also described instances where product-impact conclusions relied heavily on passing finished-product results such as sterility, endotoxin, and environmental-monitoring results.

This provides an important GMP principle:

Passing final testing does not automatically demonstrate that a manufacturing deviation had no impact on product quality.

A robust investigation should evaluate the event scientifically and determine:

• What happened?
• What was the most probable root cause?
• Could other batches, products, equipment, or processes be affected?
• What historical deviations or complaints show similar signals?
• What corrective and preventive actions are required?
• How will CAPA effectiveness be demonstrated?

For sterile manufacturing, these questions are especially important because contamination may not necessarily be uniformly distributed throughout a batch.

3. Media Fills Must Represent Actual Aseptic Risk

FDA also identified significant concerns with the site's aseptic process simulations.

According to the Warning Letter, media fills did not adequately represent maximum aseptic intervention counts, certain inherent interventions were not sufficiently documented, and the number of units used in media fills was considered inadequate. FDA emphasized the importance of incorporating worst-case conditions into process simulations. 

A strong media-fill program should therefore be based on the actual risks of commercial manufacturing.

It should consider, as applicable:

• Routine and non-routine interventions.
• Maximum or appropriately challenging intervention frequency.
• Representative operating duration.
• Number and activities of operators.
• Equipment setup and adjustments.
• Material transfers.
• Line stoppages and corrective interventions.
• Maximum exposure of sterile product and critical surfaces.
• Sufficient simulation batch size.

A media fill should not simply be designed to pass. It should challenge the aseptic process sufficiently to provide meaningful evidence that the process remains capable of maintaining sterility.

4. Cleanroom Behavior Is Also an Engineering Issue

The Warning Letter described poor aseptic practices observed during manufacturing. FDA also raised broader concerns involving processing-line layout, ergonomics, manipulations, barrier protection, and facility design.

This distinction is important.

When an aseptic deviation occurs, assigning the cause simply to “operator error” may overlook the conditions that made the error possible.

An effective investigation should also consider:

• Equipment ergonomics.
• Accessibility of critical components.
• Frequency of interventions.
• Barrier design.
• Personnel movement.
• Material movement.
• First-air protection.
• Available cleanroom space.
• Supervisory and Quality Unit oversight.

Training may be part of a CAPA, but training alone cannot correct an inherently difficult or contamination-prone process design.

5. Visible Particulates Require a Scientifically Capable Inspection Program

FDA also identified deficiencies in the facility's visual inspection program for sterile injectable products.

Among other issues, the agency discussed defect classification, particulate detectability, probability of detection, qualification of inspection systems, and the establishment of appropriate defect limits. FDA requested an independent assessment and remediation of the visual inspection program.

A mature visual inspection system should address:

• Classification of critical, major, and minor defects.
• Appropriate defect limits.
• Qualification of inspectors.
• Qualification and capability of automated or semi-automated systems.
• Representative challenge sets.
• Detection capability for historically observed defects.
• Trending of particulate findings.
• Complaint and recall information.
• Investigation of unusual or biological foreign matter.
• Appropriate controls over re-inspection.

The objective is not merely to remove defective units. Particulate findings can provide important information about the underlying manufacturing process and should feed back into the pharmaceutical quality system.

6. Biological Particulate Contamination Is a Serious Signal

FDA reported multiple incidents involving extrinsic contamination, including hair identified during visible particulate inspection. The agency questioned aspects of the firm's investigation and batch-disposition decisions and requested retrospective review and supporting evidence.

For sterile manufacturers, foreign biological material should trigger more than simple removal of affected units.

The investigation should consider:

• Potential source of the material.
• Personnel and gowning practices.
• Component and supplier contributions.
• Facility and equipment pathways.
• Other potentially affected batches.
• Retain-sample examination where scientifically justified.
• Complaint history.
• Recurrence and trend data.
• Potential microbiological implications.

An isolated visible defect may therefore represent a system signal, not merely an individual rejected unit.

7. CAPA Must Be Supported by Objective Evidence

Another recurring lesson from the Warning Letter is that commitments alone are not sufficient.

FDA repeatedly requested comprehensive assessments, detailed remediation plans, supporting data, effectiveness evaluations, and—in several areas—independent review.

A credible CAPA package should clearly establish:

Observation → Investigation → Root Cause → Risk Assessment → CAPA → Implementation → Effectiveness Verification

For each action, an organization should be able to demonstrate:

• What specifically was corrected.
• Who was responsible.
• When implementation occurred.
• Which documents or systems changed.
• Whether related products and processes were evaluated.
• What objective evidence demonstrates completion.
• How effectiveness will be measured.
• Whether recurrence has actually been prevented.

This is particularly important when responding to a Form FDA 483 or Warning Letter.

8. Quality Unit and Executive Management Oversight

FDA requested assessments addressing Quality Unit oversight and stated that executive management remains responsible for resolving deficiencies and systemic flaws even when an external CGMP consultant is engaged.

This is an important management lesson.

Quality oversight should not begin after an FDA investigator identifies a problem. Management review should already be capable of identifying adverse signals through:

• Deviations and investigations.
• CAPA trends.
• Environmental monitoring.
• Media-fill performance.
• Complaints.
• Particulate trends.
• Batch rejection data.
• Recalls.
• Supplier quality performance.
• Recurring human interventions.
• Process and facility risks.

The objective is to detect deterioration in the state of control before it develops into a significant regulatory finding.

9. Practical Inspection-Readiness Questions

Sterile manufacturing sites can use this Warning Letter as a prompt for internal assessment.

Ask your organization:

• Do investigations establish scientifically supported root causes?
• Are investigations expanded appropriately across related batches and products?
• Do we ever use passing final testing as the primary justification for closing significant deviations?
• Do media fills represent actual and worst-case interventions?
• Are interventions accurately documented and trended?
• Are recurring operator errors evaluated for engineering or ergonomic causes?
• Can our visual inspection program demonstrate adequate detection capability?
• Are biological particulates treated as potentially critical contamination signals?
• Does CAPA include meaningful effectiveness verification?
• Does the Quality Unit have sufficient authority and oversight?
• Can management demonstrate that significant quality risks are actively reviewed?

If several answers are uncertain, the organization may have an inspection-readiness gap that deserves attention before the next regulatory inspection.

10. Management Takeaway

The Fresenius Kabi Warning Letter illustrates an important principle of modern sterile manufacturing:

Sterility assurance is a system, not a test result.

Media fills, investigations, environmental monitoring, visual inspection, facility design, operator practices, CAPA, Quality Unit oversight, and management responsibility all contribute to the state of control.

Organizations should therefore avoid treating individual deviations as isolated events. Recurring interventions, contamination signals, particulate findings, investigation weaknesses, and ineffective CAPAs can collectively indicate a broader quality-system problem.

The strongest inspection-readiness strategy is to identify those signals internally, investigate them rigorously, and generate objective evidence of sustainable remediation before FDA asks for it.

Source: U.S. Food and Drug Administration, Fresenius Kabi USA LLC, Warning Letter 733107, September 22, 2026.